Common use of Terms Confidential Clause in Contracts

Terms Confidential. Each Party hereby acknowledges and agrees that it will not disclose the terms of the Agreement or this Amendment or any other information relating to the subject matter hereof or thereof to any third party without the express written consent of the other Party, except that (i) either Party may use the text of a written statement approved in advance by both Parties without further approval, (ii) ▇▇▇▇▇ may disclose the terms of the Agreement and this Agreement to a potential or current Sublicensee, and (iii) either Party shall have the right, following written notice to the other Party, to identify the other Party and to disclose the terms of this Agreement as required by applicable securities laws or other applicable laws or regulations. Please sign below where indicated to acknowledge your agreement to the foregoing Amendment. Sincerely, ▇▇▇▇▇ PHARMACEUTICAL GROUP, INC. By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, Ph.D. Title: CEO and President ACKNOWLEDGED AND AGREED TO This 25 day of September, ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇ HEALTH RESEARCH INSTITUTE By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇ Title: Chief Operating Officer [*************] [*************] [********] [*********] [*****] [********************** ********************] [*******] [*************] [*******] [********] [*******] [*************] [***********] [********] [*******] [*************] [******] [********] [*******] [*************] [*********] [********] [*******] [*************] [******] [********] [*******] [*************] [************] [********] [*******] [*************] [******] [********] [*******] [*************] [********] [********] [*******] [*************] [*************] [********] [*****] [*********] [********************** *********************** ************] [*******] [**************] [*********] [*****] [********************** *********************** ******************] [***************** *****************] [**************] [*********] [*****] [********************** *********************** *********************** ********] [***************** *****************] [************] [************] [************] [************] [********] [********] [********] [********] [********] [********] [********] [********] [*****] [******] [*****] [********] [*********] [******************** ******************** ******************** ***********] [*******] [*******] [*******] [*******] [************] [*************] [********] [*****] [******************** ******************** [*******] [*****] ****************] [************] [********] [********] [******] [*******] [************] [**********] [********] [**] [*******] [************] [**********] [********] [*******] [************] [**********] [********] [******] [******] [*****] [******************** ******************** ******************** *********] [*******] [************] [**********] [********] [**********] [******************** [*******] [*****] ******************** ******************** ******************** [************] [********] [********] [*****] ****************] [*******] [************] [********] [********] [*******] [************] [**********] [********] [*******] [*******] [************] [***********] [********] [*******] [*****************************************************************************************] This Agreement is made as of the 25 day of September 2001, by and between ▇▇▇▇▇ Pharmaceutical Group, Inc., a Delaware corporation (the “Company”), and the Ottawa Health Research Institute (“Purchaser”).

Terms Confidential. Each Party hereby acknowledges and agrees that it will not disclose the terms of the Agreement or this Amendment or any other information relating to the subject matter hereof or thereof to any third party without the express written consent of the other Party, except that (i) either Party may use the text of a written statement approved in advance by both Parties without further approval, (ii) ▇▇▇▇▇ may disclose the terms of the Agreement and this Agreement to a potential or current Sublicensee, and (iii) either Party shall have the right, following written notice to the other Party, to identify the other Party and to disclose the terms of this Agreement as required by applicable securities laws or other applicable laws or regulations. Please sign below where indicated to acknowledge your agreement to the foregoing Amendment. Sincerely, ▇▇▇▇▇ PHARMACEUTICAL GROUP, INC. By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, Ph.D. Title: CEO and President ACKNOWLEDGED AND AGREED TO This 25 day of September, ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇ HEALTH RESEARCH INSTITUTE By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇ Title: Chief Operating Officer [*************] [*************] [********] [*********] [*****] [********************** ********************] [*******] Pending [*************] [*******] [********] [*******] Pending [*************] [***********] [********] [*******] Pending [*************] [******] [********] [*******] Pending [*************] [*********] [********] [*******] Pending [*************] [******] [********] [*******] Pending [*************] [************] [********] [*******] Pending [*************] [******] [********] [*******] Pending [*************] [********] [********] [*******] Pending [*************] [*************] [********] [*****] [*********] [********************** *********************** ************] [*******] Pending [**************] [*********] [*****] [********************** *********************** ******************] [***************** *****************] Patentability study being performed [**************] [*********] [*****] [********************** *********************** *********************** ********] [***************** *****************] Patentability study being performed [************] [************] [************] [************] [********] [********] [********] [********] [********] [********] [********] [********] [*****] [******] [*****] [********] [*********] [******************** ******************** ******************** ***********] [*******] [*******] [*******] [*******] Pending Pending Pending Pending [************] [*************] [********] [*****] [******************** ******************** [*******] Allowed [*****] ****************] [************] [********] [********] [******] [*******] Pending [************] [**********] [********] [**] [*******] Pending [************] [**********] [********] [*******] Pending [************] [**********] [********] [******] [******] [*****] [******************** ******************** ******************** *********] [*******] Pending [************] [**********] [********] [**********] [******************** [*******] Pending [*****] ******************** ******************** ******************** [************] [********] [********] [*****] ****************] [*******] Pending [************] [********] [********] [*******] Pending [************] [**********] [********] [*******] [*******] Pending [************] [***********] [********] [*******] [*****************************************************************************************] Pending * indicates that a patent application is in the process of preparation, but has not yet been filed. This Agreement is made as of the 25 day of September 2001, by and between ▇▇▇▇▇ Pharmaceutical Group, Inc., a Delaware corporation (the “Company”), and the Ottawa Health Research Institute (“Purchaser”).